Therapeutic and diagnostic probes
The present invention provides compositions and methods of use of nanoparticle-based probes for in vivo imaging and therapy. The probes can be used to track diseased target cells by non-invasive imaging in the near-infrared range. Additionally, the probes can induce cell death of the target cells via photodynamic treatment.
1. A probe comprising a nanocarrier attached to both (1) an imaging agent, wherein the imaging agent is a cyanine dye; and (2) a therapeutic agent, which is IRDYE700DX, wherein said nanocarrier is an antibody or a fragment thereof.
2. The probe of claim 1 , wherein said therapeutic agent is attached to said nanocarrier via a first linker.
3. The probe of claim 2 , wherein said imaging agent is attached to said nanocarrier via a second linker.
4. A method for detecting a target cell in an individual, said method comprising:
(a) contacting said target cell with a probe comprising a nanocarrier attached to both (1) an imaging agent, which imaging agent is a cyanine dye; and (2) a therapeutic agent, wherein the therapeutic agent is IRDYE700DX, wherein the probe selectively associates with the said target cell, wherein said nanocarrier is an antibody or fragment thereof; and
(b) detecting said imaging agent thereby providing an indication of the presence and/or location of said target cell in the individual.
5. The method of claim 4 , wherein said contacting comprises systemic administration to the individual, local administration to a tumor, or administration to a surgical site.
6. The method of claim 4 , wherein said target cell is a cell of a solid tumor.
7. The method claim 4 , further comprising exposing said therapeutic agent to a photoactivating light, thereby inducing apoptosis and/or necrosis of said target cell in the individual.
8. A method for inducing cell death in a target cell in an individual, said method comprising:
(a) contacting said target cell with a probe comprising a nanocarrier attached to both (1) an imaging agent, which imaging agent is a cyanine dye; and (2) a therapeutic agent, wherein the therapeutic agent is IRDYE700DX, wherein the probe selectively associates with said target cell, wherein said nanocarrier is an antibody or fragment thereof; and
(b) exposing said therapeutic agent to a photoactivating light, thereby inducing apoptosis and/or necrosis of said target cell in the individual.
9. The method of claim 8 , wherein said contacting comprises systemic administration to the individual, local administration to a tumor, or administration to a surgical site.